[HTML][HTML] Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - thieme-connect.com
Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
[引用][C] Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - tobias-lib.ub.uni-tuebingen.de
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease:
Rationale and Review of the Evidence Dual Pathway Inhibition for Vascular Protection in …
Rationale and Review of the Evidence Dual Pathway Inhibition for Vascular Protection in …
[PDF][PDF] Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - academia.edu
Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dualantiplatelet …
disease, the residual risk of recurrent atherothrombotic events remains high. Dualantiplatelet …
[引用][C] Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - ub01.uni-tuebingen.de
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease:
Rationale and Review of the Evidence Dual Pathway Inhibition for Vascular Protection in …
Rationale and Review of the Evidence Dual Pathway Inhibition for Vascular Protection in …
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - europepmc.org
Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - pubmed.ncbi.nlm.nih.gov
Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …